Perrigo's partner receives final approval for Epinastine HCl ophthalmic solution

Nov 2 2011NewsGuard 100/100 Score

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05%, a generic version of Elestat®. Perrigo will commence shipment of the product immediately.

Elestat® is a sterile ophthalmic solution containing epinastine that is indicated for the prevention of ocular itching associated with allergic conjunctivitis. Estimated annual brand sales for the product prior to generic market formation were $30 million, according to Wolters Kluwer data.

Perrigo's Chairman and CEO Joseph C. Papa stated, "Perrigo is excited to launch another new product in the ophthalmic category, as part of our extended topical strategy. This product is another example of Perrigo's commitment to expand our portfolio and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare products."

SOURCE Perrigo Company

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , ,

Comments (0)

Suggested Reading

Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care
Tiny molecule offers hope in reducing opioid side effects
Obesity crisis in the U.S. expected to worsen by 2050
Obesity medication liraglutide is safe and effective in children aged 6 to <12 years
Antibiotic resistance threatens millions of lives worldwide
Early RSV vaccination in pregnancy provides best protection for newborns
GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study focuses on COPD progression in younger populations